A new research collaboration potentially covering multiple therapy types for the treatment of cancer was unveiled by Moderna Inc and Immatics NV on 11 September. The partnership brings together Moderna’s messenger RNA (mRNA) technology with Immatics’ expertise in engineering T cell receptors (TCRs) and developing biologics. The goal is to develop bispecific therapies, vaccines and cell therapies for cancer.
